Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.40+0.15 (+1.62%)
Close on Nov 17, 2026Market cap $558.21MP/E 10.1Yield –
Zevra Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Zevra Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $14.93M, down 42.6% year over year. For fiscal 2025 it was $12.74M, down 69.7% from the year before. Over ten years it grew -0.9% a year on average. The highest annual figure on record is $42.10M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.74M | -69.7% |
| FY2024 | Dec 31, 2024 | $42.10M | +5.8% |
| FY2023 | Dec 31, 2023 | $39.81M | +101.0% |
| FY2022 | Dec 31, 2022 | $19.80M | +94.9% |
| FY2021 | Dec 31, 2021 | $10.16M | +14.9% |
| FY2020 | Dec 31, 2020 | $8.84M | -54.5% |
| FY2019 | Dec 31, 2019 | $19.42M | -53.5% |
| FY2018 | Dec 31, 2018 | $41.76M | +102.8% |
| FY2017 | Dec 31, 2017 | $20.59M | +0.6% |
| FY2016 | Dec 31, 2016 | $20.47M | +47.0% |
| FY2015 | Dec 31, 2015 | $13.93M | +16.9% |
| FY2014 | Dec 31, 2014 | $11.92M | +253.9% |
| FY2013 | Dec 31, 2013 | $3.37M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.49M | +30.7% |
| Q1 FY2026 | Mar 31, 2026 | $4.39M | +34.8% |
| Q4 FY2025 | Dec 31, 2025 | $2.62M | -68.6% |
| Q3 FY2025 | Sep 30, 2025 | $3.43M | -68.6% |
| Q2 FY2025 | Jun 30, 2025 | $3.43M | -67.4% |
| Q1 FY2025 | Mar 31, 2025 | $3.26M | -73.5% |
| Q4 FY2024 | Dec 31, 2024 | $8.35M | -26.9% |
| Q3 FY2024 | Sep 30, 2024 | $10.95M | -11.0% |
| Q2 FY2024 | Jun 30, 2024 | $10.52M | +41.5% |
| Q1 FY2024 | Mar 31, 2024 | $12.28M | +41.8% |
| Q4 FY2023 | Dec 31, 2023 | $11.42M | +74.6% |
| Q3 FY2023 | Sep 30, 2023 | $12.30M | +128.4% |
| Q2 FY2023 | Jun 30, 2023 | $7.43M | +55.0% |
| Q1 FY2023 | Mar 31, 2023 | $8.66M | +180.8% |
| Q4 FY2022 | Dec 31, 2022 | $6.54M | +132.9% |
| Q3 FY2022 | Sep 30, 2022 | $5.39M | +140.5% |
| Q2 FY2022 | Jun 30, 2022 | $4.80M | +68.4% |
| Q1 FY2022 | Mar 31, 2022 | $3.08M | +36.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.81M | -8.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.24M | +31.0% |
| Q2 FY2021 | Jun 30, 2021 | $2.85M | +45.8% |
| Q1 FY2021 | Mar 31, 2021 | $2.27M | +6.5% |
| Q4 FY2020 | Dec 31, 2020 | $3.05M | +23.9% |
| Q3 FY2020 | Sep 30, 2020 | $1.71M | -52.7% |
| Q2 FY2020 | Jun 30, 2020 | $1.95M | -59.3% |
| Q1 FY2020 | Mar 31, 2020 | $2.13M | -75.1% |
| Q4 FY2019 | Dec 31, 2019 | $2.47M | -60.9% |
| Q3 FY2019 | Sep 30, 2019 | $3.62M | -72.9% |
| Q2 FY2019 | Jun 30, 2019 | $4.80M | -54.2% |
| Q1 FY2019 | Mar 31, 2019 | $8.53M | -26.7% |
| Q4 FY2018 | Dec 31, 2018 | $6.30M | +13.9% |
| Q3 FY2018 | Sep 30, 2018 | $13.33M | +111.8% |
| Q2 FY2018 | Jun 30, 2018 | $10.49M | +125.5% |
| Q1 FY2018 | Mar 31, 2018 | $11.64M | +182.9% |
| Q4 FY2017 | Dec 31, 2017 | $5.54M | -30.5% |
| Q3 FY2017 | Sep 30, 2017 | $6.29M | +46.8% |
| Q2 FY2017 | Jun 30, 2017 | $4.65M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.11M | – |
| Q4 FY2016 | Dec 31, 2016 | $7.96M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.29M | – |
See a number that looks wrong?